期刊文献+

羟基喜树碱联合化疗治疗晚期消化系统恶性肿瘤临床观察 被引量:6

Effects of Hydroxycamptothecin Combined Chemotherapy in Advanced Digestive System Malignant Tumors
下载PDF
导出
摘要 目的 :观察含羟基喜树碱 (HCPT)联合化疗方案治疗晚期消化系统恶性肿瘤的疗效及毒副作用。方法 :使用HCPT 6mg/m2 /d维持 4~ 6小时d1~ 10联合PLF、ELF、PPF、PAF等化疗方案治疗晚期消化系统恶性肿瘤 49例 ,其中胃癌 19例 ,结肠癌 15例 ,食管癌 11例 ,胰腺癌 4例。结果 :有效率 (RR)分别为胃癌 5 7.9% ,结肠癌 46 .7% ,食管癌 5 3.1% ,胰腺癌 5 0 .0 % ;CR 2例 ,PR 2 4例 ,NC 15例 ,PD 8例 ;总有效率 5 3.1%。毒性反应 :部分患者伴有轻度的恶心呕吐、白细胞减少、口腔粘膜炎等。结论 :治疗晚期消化系统恶性肿瘤 ,在常用的化疗方案基础上用HCPT ,具有毒性小 ,耐受性好 ,疗效高的特点 ,值得进一步推广应用。 Objective:To observe the efficacy and toxicity of hydroxycamptothecin(HCPT) combined chemotherapy in the treatment of the patients with digestive system malignant tumor. Methods: 49 cases with digestive system malignant tumor were treated with HCPT 6mg/m 2 /d iv gtt ,maintaining 4~6h,d1~10, combined with PLF,ELF,PPF,and PAF. Results:The total remission rate(CR+PR)was 53.1%,with CR 2 cases,PR 24 cases,NC 15 cases and PD 8 cases.The major toxicity were mild nausea, vomiting,neucopenia,nucositis and so on.Conclusion: HCPT was added to common chemothrapy in the treatment of advanced digestive system malignant tumor,this method is characterized by small toxicity,good toleration,and high efficacy.
作者 张闯
出处 《四川肿瘤防治》 2002年第1期10-11,共2页 Sichuan Journal of Cancer Control
关键词 羟基喜树碱 肿瘤 消化系统 联合化疗 晚期 Hydroxycamptothecin Malignant tumor Digestive system Combined chemotherapy
  • 相关文献

参考文献3

二级参考文献8

  • 1管忠震,何友兼,刘茂珍,周中梅.大剂量醛氢叶酸合并氟脲嘧啶(HDCF/5Fu)治疗晚期胃肠道癌的探讨[J].癌症,1989,8(6):421-424. 被引量:82
  • 2郑秀立,中国癌症杂志,1992年,2卷,1期,41页
  • 3潘启超,实用肿瘤杂志,1990年,5卷,3期,182页
  • 4Wang Z,Mol Pharmacol,1996年,49卷,269页
  • 5李继华,中国肿瘤临床,1996年,23卷,134页
  • 6李建人,中华理疗杂志,1995年,18卷,1313页
  • 7Tan K B,J Natl Cancer Inst,1989年,81卷,1732页
  • 8凌义和,俞伟娟,胥彬.10-羟基喜树碱对小鼠肝癌细胞转运嘧啶核苷的影响[J]Acta Biochimica et Biophysica Sinica,1983(06).

共引文献209

同被引文献34

  • 1Park SH, Sung JY, Han SH, et al. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as secondline treatment in advanced colorectal cancer patients with irinotecan failure:a Korean single-center experience[J]. Jpn J Clin Oncol ,2005, 359:531-535.
  • 2Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase Ⅲ trial [ J ]. Eur J Cancer, 2002,38( suppl 2) : 15-20.
  • 3Van Cutsem EV, Hoff PM, Harper P,et al. Oral Capecitabine vs intravenous 5-fluorouracil and leucovorin:integTated efficacy data and novel analyses from two large,randomised phase Ⅲ trials[J]. Br J Cancer, 2004,90 (6) : 1190-1197.
  • 4Jaxel C, Kohm K W, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalion Topoisomerase evidence for a specific receptor site and a relation to antitumor activity [ J]. Cancer Res, 1989,49(6) : 1465-1469.
  • 5LABIANCA R, MASONI S,PANCERA G,et al. Feeicacy of adjuvant fluorouracil and fo - linic acid in colon cancer[J]. Lancet,1995, 345 ( 8955 ) :9392944.
  • 6ROWE P M. Camptothecin: new enthusiasm for and old drug[ J].Lancet, 1995, 347: 892.
  • 7ROTHENBERH M L, LCKARDT J R,KUHN J G, et al. Phase Ⅱ trial of ifinotecan in patients with progressive of rapidly recurrent coloerctal cancer[J]. J Clin Oncol, 1996, 14(4): 112821135.
  • 8BODLEY A, LIU L F, ISRAEL M, et al. DNA topoisomerase Ⅱ mediated, and daunoru - bicin of doxorubicin corgeners vdth DNA[J]. Cancer Res, 1989, 29 (21) : 5969 -5978.
  • 9BLEIBERG H. Rloe of chemotherapy for advanced colorectal cancer. New opportuni - tes [ J ]. Semin Oncol, 1996, 23:42252.
  • 10DECAPRIO J A, MAYER R J, GONIN R, et al. Fluorouracil and highdose leuco -vorin in previously untreated patients with advanced adenocarcinoma of the pancreas : re - suits of a phase * trial[J]. J Clin Oncol, 1991,9(12): 2128 -2133.

引证文献6

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部